Prognostic significance of the cachexia index in patients with unresectable advanced gastric cancer receiving palliative chemotherapy: a retrospective single-center study

[1] Lei X(2022)Short-and long-term outcomes of laparoscopic versus open gastrectomy in patients with gastric cancer: a systematic review and meta-analysis of randomized controlled trials World J Surg Oncol 20 405-606

[2] Wang Y(2019)A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial Gastric Cancer 22 598-5355

[3] Shan F(2019)Feasibility of endoscopic treatment and predictors of lymph node metastasis in early gastric cancer World J Gastroenterol 25 5344-1671

[4] Li S(2018)Feasibility of laparoscopic distal gastrectomy for stage i gastric cancer in patients outside of clinical trials J Gastrointest Surg 22 1665-2414

[5] Jia Y(2016)Advanced gastric cancer: current treatment landscape and future perspectives World J Gastroenterol 22 2403-40

[6] Miao R(2021)First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial Lancet 398 27-2589

[7] Hosoda K(2019)Neutrophil-to-lymphocyte ratio as a prognostic indicator in patients with unresectable gastric cancer Anticancer Res 39 2583-621

[8] Azuma M(2022)Neutrophil-to-lymphocyte ratio and C-reactive protein-to-albumin ratio as prognostic factors for unresectable advanced or recurrent gastric cancer Langenbecks Arch Surg 407 609-495

[9] Katada C(2023)Neutrophil-to-lymphocyte ratio before each chemotherapy line predicts clinical outcomes in patients with unresectable gastric cancer Oncol Lett 25 98-454

[10] Moriya H(2011)Definition and classification of cancer cachexia: an international consensus Lancet Oncol 12 489-93

[1] Lei X(2022)Short-and long-term outcomes of laparoscopic versus open gastrectomy in patients with gastric cancer: a systematic review and meta-analysis of randomized controlled trials World J Surg Oncol 20 405-606

[2] Wang Y(2019)A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial Gastric Cancer 22 598-5355

[3] Shan F(2019)Feasibility of endoscopic treatment and predictors of lymph node metastasis in early gastric cancer World J Gastroenterol 25 5344-1671

[4] Li S(2018)Feasibility of laparoscopic distal gastrectomy for stage i gastric cancer in patients outside of clinical trials J Gastrointest Surg 22 1665-2414

[5] Jia Y(2016)Advanced gastric cancer: current treatment landscape and future perspectives World J Gastroenterol 22 2403-40

[6] Miao R(2021)First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial Lancet 398 27-2589

[7] Hosoda K(2019)Neutrophil-to-lymphocyte ratio as a prognostic indicator in patients with unresectable gastric cancer Anticancer Res 39 2583-621

[8] Azuma M(2022)Neutrophil-to-lymphocyte ratio and C-reactive protein-to-albumin ratio as prognostic factors for unresectable advanced or recurrent gastric cancer Langenbecks Arch Surg 407 609-495

[9] Katada C(2023)Neutrophil-to-lymphocyte ratio before each chemotherapy line predicts clinical outcomes in patients with unresectable gastric cancer Oncol Lett 25 98-454

[10] Moriya H(2011)Definition and classification of cancer cachexia: an international consensus Lancet Oncol 12 489-93